iBio (NASDAQ:IBIO) Releases Earnings Results, Beats Estimates By $0.03 EPS

Key Points

• iBio reported quarterly EPS of negative $0.04, beating analysts’ consensus estimate of negative $0.07 by $0.03.
• IBIO opened at $1.40, with a market capitalization of approximately $69.6 million; the stock has traded between $0.77 and $3.82 over the past year.
• Analyst sentiment remains generally positive, with an average “Buy” rating and a $5.00 price target, although one research firm maintains a sell rating. Institutional investors own 7.9% of the company.

iBio (NASDAQ:IBIO - Get Free Report) issued its earnings results on Friday. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.03, Zacks reports.

iBio Price Performance

IBIO stock opened at $1.40 on Friday. The company has a 50 day moving average price of $1.49 and a 200 day moving average price of $1.84. iBio has a fifty-two week low of $0.77 and a fifty-two week high of $3.82. The stock has a market capitalization of $69.55 million, a PE ratio of -2.41 and a beta of 1.30.

Institutional Trading of iBio

Several institutional investors and hedge funds have recently added to or reduced their stakes in IBIO. XTX Topco Ltd acquired a new stake in iBio during the 4th quarter worth $71,000. Persistent Asset Partners Ltd bought a new position in shares of iBio in the 4th quarter worth $76,000. Susquehanna International Group LLP acquired a new stake in shares of iBio during the third quarter worth $37,000. Cubist Systematic Strategies LLC bought a new stake in iBio in the first quarter valued at about $224,000. Finally, State Street Corp increased its holdings in iBio by 116.3% in the fourth quarter. State Street Corp now owns 72,899 shares of the company's stock valued at $141,000 after purchasing an additional 39,200 shares during the last quarter. 7.90% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

IBIO has been the topic of a number of recent analyst reports. Chardan Capital restated a "buy" rating and issued a $5.00 price target on shares of iBio in a research report on Thursday, July 2nd. B. Riley Financial began coverage on shares of iBio in a report on Friday, June 5th. They set a "buy" rating and a $6.00 price objective for the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of iBio in a research note on Wednesday, June 24th. Raymond James Financial initiated coverage on iBio in a report on Monday, June 8th. They issued an "outperform" rating and a $5.00 target price on the stock. Finally, Wall Street Zen downgraded iBio from a "hold" rating to a "sell" rating in a research report on Sunday, August 23rd. Three analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, iBio currently has an average rating of "Buy" and an average price target of $5.00.

iBio Company Profile

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source